Hepcinat Plus - (Sofosbuvir 400 mg + Daclatasvir 60 mg) Tablet
Hepcinat Plus Tablet: Each tablet contains Sofosbuvir 400 mg and Daclatasvir 60 mg.
Sofosbuvir targets the Hepatitis C virus directly to prevent it from making copies of itself in the liver. Sofosbuvir attaches itself to the genetic information called RNA to block the multiplication of the virus.
Daclatasvir is a Direct-Acting Antiviral (DAA) against the hepatitis C virus.
Sofosbuvir and Daclatasvir combination indicated for the treatment of chronic hepatitis C (CHC) infection as part of a combination antiviral treatment regimen.
The response to treatment will vary based on the starting factors and viral factors.
Recommended Dose in Adults
The recommended dose of Sofosbuvir 400 mg and Daclatasvir 60 mg tablets is one, that is taken once a day with or without food.
Sofosbuvir and Daclatasvir combination should be used in combination with or without ribavirin for the treatment of CHC in adults.
Discontinuation of Dosing
If other agents used in combination with Sofosbuvir and Dacalatasvir are permanently discontinued, the combination of Sofosbuvir and Dacaltasvir should also be discontinued.
The most common side effects seen with Sofosbuvir and Daclatasvir in combination with Ribavirin were fatigue and headache. There are some rare side effects, such as fatigue, headache, insomnia, nausea, pruritus, anemia, asthenia, rash, anorexia, chills, Infulenza such as illness
When Sofosbuvir and Daclatasvir are used in combination with Ribavirin, the contraindications for these agents also apply to combination therapies.
Combination therapy of Sofosbuvir with Daclatasvir with Ribavirin is contraindicated in women who are pregnant or could become pregnant and in men whose partners are pregnant because of the risks of birth defects and fetal death associated with Ribavirin.
Interactions with other Drugs
Medications that are potent intestinal P-gp inducers may alter the levels of Sofosbuvir. Consult the full prescribing information before use for possible drug interactions.
Pregnancy: When Ribavirin is used with this combination, it can lead to birth defects and death of the fetus. Avoid pregnancy in female patients and female partners of male patients.
Because of the possible side effects of the drug in breast-fed infants, it is necessary to decide whether to stop breast-feeding or discontinue treatment with ribavirin-containing regimens, taking into account the importance of the therapy to the mother.
You can buy Hepcinat Plus (Sofosbuvir + Daclatasvir), a new hepatitis C drug in India at an affordable price at Oddway International.
